ArticleAllergy, asthma & immunology research2026

Benefits of CMAB007 in Chinese Patients Having Inadequately Controlled Moderate/Severe Asthma With Increased Total IgE: A Randomized Phase 3 Trial.

Kefang Lai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.